Alimera Sciences: Company Achieves Breakeven Pretax Cash Flow In 2Q, 2017 Despite Slow Unit Demand For Iluvien

Alimera has made dramatic improvements in its cash flow situation and has done a very respectable job in building sales. Alimera is not far away from being a cash generating, profitable pharmaceutical company.